At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 229 enrolled
Drug / intervention
Tislelizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating Tislelizumab and Pamiparib for Solid Tumors. Completed, enrolled 229 participants across 29 sites in 6 countries.
Detailed Summary
This trial studied the safety, pharmacokinetics, and antitumor activity of the anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) BGB-A317 (tislelizumab) in combination with the poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor BGB-290 (pamiparib) in participants with advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesAustralia, France, New Zealand, Spain, United Kingdom, United States
CollaboratorsMyriad Genetic Laboratories, Inc.
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartFeb 2016
Primary CompletionSep 2020
TodayJul 2026
First PostedJan 21, 2016
Enrollment StartFeb 2, 2016
Primary CompletionSep 9, 2020
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 10.4 years ago
Interventions
Tislelizumabbiological
Pamiparibdrug